On December 3, BioMap (000710.SZ) stated on the investor interaction platform that the company currently does not have liver disease genetic drug products, nor does it have research and development of tumor genetic vaccines. The company is dedicated to fully converting gene sequencing technology into clinical applications, focusing on areas such as reproductive health, genetic disease testing, tumor detection, and technology services. The company currently provides sequencing services for some innovative drug companies.
贝瑞基因(000710.SZ)：目前并无肝病基因药物产品，亦无肿瘤基因疫苗研发
Berry Genomics (000710.SZ): Currently, there are no gene drugs for liver disease, nor any tumor gene vaccine research and development.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.